Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder
about
Activation of adenosine(1) (A(1)) receptors suppresses head shakes induced by a serotonergic hallucinogen in rats.Emerging drugs for the treatment of anxiety50 years of hurdles and hope in anxiolytic drug discoveryMetabotropic glutamate receptors: from the workbench to the bedside.The age of anxiety: role of animal models of anxiolytic action in drug discovery.Pharmacological and pharmacokinetic properties of JNJ-40411813, a positive allosteric modulator of the mGlu2 receptorMolecular Insights into Metabotropic Glutamate Receptor Allosteric ModulationPost-traumatic stress disorder: emerging concepts of pharmacotherapy.Positive allosteric modulators of the metabotropic glutamate receptor 2 for the treatment of schizophrenia.The mGlu2/3 Receptor Agonists LY354740 and LY379268 Differentially Regulate Restraint-Stress-Induced Expression of c-Fos in Rat Cerebral CortexTranslating glutamate: from pathophysiology to treatment.Activation of adenosine₁ receptors induces antidepressant-like, anti-impulsive effects on differential reinforcement of low-rate 72-s behavior in ratsNAAG peptidase inhibitors and deletion of NAAG peptidase gene enhance memory in novel object recognition test.Targeting the glutamatergic system to develop novel, improved therapeutics for mood disordersPractical Strategies and Concepts in GPCR Allosteric Modulator Discovery: Recent Advances with Metabotropic Glutamate ReceptorsMetabotropic glutamate receptor ligands as potential therapeutics for addictionInvolvement of glutamatergic and GABAergic systems in nicotine dependence: Implications for novel pharmacotherapies for smoking cessation.Neuroimaging and physiological evidence for involvement of glutamatergic transmission in regulation of the striatal dopaminergic system.Targeting glutamatergic signaling for the development of novel therapeutics for mood disordersSynaptic Plasticity, Metaplasticity and Depression.Metabotropic glutamate receptors: physiology, pharmacology, and disease.Therapeutic potential of targeting group III metabotropic glutamate receptors in the treatment of Parkinson's disease.Contextual conditioning in rats as an animal model for generalized anxiety disorder.mGluR2 positive allosteric modulators: a patent review (2009 - present).Glutamate-based anxiolytic ligands in clinical trials.Progress toward advanced understanding of metabotropic glutamate receptors: structure, signaling and therapeutic indicationsInvestigational drugs under development for the treatment of PTSD.An allosteric modulator of metabotropic glutamate receptors (mGluR₂), (+)-TFMPIP, inhibits restraint stress-induced phasic glutamate release in rat prefrontal cortexEvaluation of single and multiple doses of a novel mGlu2 agonist, a potential antipsychotic therapy, in healthy subjects.Molecular determinants of positive allosteric modulation of the human metabotropic glutamate receptor 2.Group II mGluRs suppress hyperexcitability in mouse and human nociceptors.Neuroprotection and Functional Recovery Associated with Decreased Microglial Activation Following Selective Activation of mGluR2/3 Receptors in a Rodent Model of Parkinson's Disease.Altered hippocampal expression of glutamate receptors and transporters in GRM2 and GRM3 knockout miceTargeting glial physiology and glutamate cycling in the treatment of depression.The role of group II metabotropic glutamate receptors in cognition and anxiety: comparative studies in GRM2(-/-), GRM3(-/-) and GRM2/3(-/-) knockout mice.Pharmacokinetic and pharmacodynamic characterisation of JNJ-40411813, a positive allosteric modulator of mGluR2, in two randomised, double-blind phase-I studies.Broad spectrum efficacy with LY2969822, an oral prodrug of metabotropic glutamate 2/3 receptor agonist LY2934747, in rodent pain models.Increased metabotropic glutamate 2/3 receptor binding in the perigenual anterior cingulate cortex of Cloninger type 2 alcoholics: a whole-hemisphere autoradiography study.Metabotropic Glutamate2 Receptors Play a Key Role in Modulating Head Twitches Induced by a Serotonergic Hallucinogen in Mice.Group II Metabotropic Glutamate Receptors: Role in Pain Mechanisms and Pain Modulation
P2860
Q24652204-4E1A09C8-BCBC-4F0A-93D1-6F460141C883Q28083141-45B8C5CB-009F-4F1F-A7E4-467B24E834A9Q28297569-FBA843BE-30BD-40B7-ADFD-D12CC0169030Q30448778-972E8DF5-4322-4EC8-867A-7D610386E9AAQ30462832-E9CC214C-94BC-4528-8AC4-E8FC9D343387Q34463460-9DD76899-D84C-453B-A7D0-56087A9E6B63Q34468639-09E0377F-5995-4509-8ADC-B1A03A376689Q34981801-4E4EC4AC-AC1D-4822-B62D-13B38DC140BFQ34988708-C49A636E-7AC8-40DA-9615-1B76D11615DAQ35623415-14825C4D-40B0-4330-AAFA-4EB889D45E77Q35739457-124A79BC-811E-484E-B591-24E40BD2527CQ35913141-298374EB-E871-4C68-A5B5-82549C582C9CQ36675499-10D7DE55-D8A7-46EC-85E5-80C5E7383EFCQ37143117-BC2FA4FE-CCF4-4F2D-B573-ECC1EE5EAE2EQ37183072-6D031530-7ACA-4CBC-A985-58D71F0F9D7FQ37280041-DD188DE4-FC83-4CBB-977E-AF7C201A61B5Q37315470-9DB04656-3B58-44DA-B565-F4E5150335EAQ37352417-338B5486-55B1-474D-B742-38F408A45E18Q37481603-1B8246A4-241C-4FAD-A38D-2B07326B6095Q37668039-40056F59-DF2B-4D37-91B8-FAA11AB1A38DQ37670222-86786067-DF11-4262-8EB2-0E419B90F2D8Q37782115-3EF978DF-B6BF-459A-87EC-CA195604E663Q37837718-E14A2E47-D645-4C5E-A7E7-8D159A08D45DQ38085707-7FE27B6E-A453-4837-95BB-DAF61AFAA610Q38110306-4F92FF89-94CB-4B78-8A64-DB6D5D2F3936Q38209092-7A36C156-D4BB-4D33-9EFF-C4BEFC87604AQ38378939-9AB188C3-7927-4C97-977F-D894CA5367FDQ38565386-20B32A7C-E1C4-4518-B151-986890BA9730Q38982230-B3D795DC-A194-441A-8F0C-654AA0BF99B5Q39062474-88CEBC2A-4EF6-40E7-98AF-A3945DB667F3Q41699835-6716CAD2-269C-45FF-804F-6A61CD696DCDQ41774971-71BBF1D8-D9B0-4F35-BF5F-74437911AC13Q41779206-298171F2-A8F8-4226-8D06-A8E335D75E55Q42056797-01B337E5-C245-4887-93B5-712EAAF5D00AQ43058779-B35BA857-C983-4CCD-B3D6-DE350CC20698Q47740655-0B2A5756-FB86-465D-8B6C-A549C07A82BCQ48318347-1E278A8D-92F0-412A-BFAB-FFDD9BD3E678Q48447104-A6F95F6D-30CD-451B-A081-AC865DD01E1FQ54988063-F999F998-BBE8-4442-B494-A969E012B497Q57816814-E39E7A25-6CC9-4A02-9176-BF01E2D8B627
P2860
Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Efficacy and tolerability of a ...... f generalized anxiety disorder
@ast
Efficacy and tolerability of a ...... f generalized anxiety disorder
@en
Efficacy and tolerability of a ...... f generalized anxiety disorder
@nl
type
label
Efficacy and tolerability of a ...... f generalized anxiety disorder
@ast
Efficacy and tolerability of a ...... f generalized anxiety disorder
@en
Efficacy and tolerability of a ...... f generalized anxiety disorder
@nl
prefLabel
Efficacy and tolerability of a ...... f generalized anxiety disorder
@ast
Efficacy and tolerability of a ...... f generalized anxiety disorder
@en
Efficacy and tolerability of a ...... f generalized anxiety disorder
@nl
P2093
P356
P1476
Efficacy and tolerability of a ...... f generalized anxiety disorder
@en
P2093
Darryle D Schoepp
Eduardo Dunayevich
Gary D Tollefson
Janelle Erickson
Louise Levine
Ronald Landbloom
P2888
P304
P356
10.1038/SJ.NPP.1301531
P407
P577
2008-06-01T00:00:00Z
P5875
P6179
1024744057